Germline Risk Contribution to Genomic Instability in Multiple Myeloma

por Janz, Siegfried, Zhan, Fenghuang, Sun, Fumou, Cheng, Yan, Pisano, Michael, Yang, Ye, Goldschmidt, Hartmut, Hari, Parameswaran
Publicado 2019

MK2 is a therapeutic target for high-risk multiple myeloma

por Gu, Chunyan, Cheng, Haibo, Yang, Hongbao, Bian, Yong, Wang, Yaohui, Zhang, Yifen, Pisano, Michael, Hu, Gang, Yang, Ye
Publicado 2018

Baicalin regulates autophagy to interfere with small intestinal acute graft-versus-host disease

por Sun, Xiaoqi, Pisano, Michael, Xu, Longjin, Sun, Fumou, Xu, Jie, Zheng, Wei, Liu, Xiujuan, Zhang, Yanyu, Sun, Runjie, Cui, Xing
Publicado 2022

WDR26 and MTF2 are therapeutic targets in multiple myeloma

por Sun, Fumou, Cheng, Yan, Riordan, Jesse D., Dupuy, Adam, Dubois, Wendy, Pisano, Michael, Dong, Jing, Mock, Beverly, Zhan, Fenghuang, Hari, Parameswaran, Janz, Siegfried
Publicado 2021

Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma

por Pisano, Michael, Cheng, Yan, Sun, Fumou, Dhakal, Binod, D’Souza, Anita, Chhabra, Saurabh, Knight, Jennifer M., Rao, Sridhar, Zhan, Fenghuang, Hari, Parameswaran, Janz, Siegfried
Publicado 2021

IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma

por Pisano, Michael D., Sun, Fumou, Cheng, Yan, Parashar, Deepak, Zhou, Vivian, Jing, Xuefang, Sompallae, Ramakrishna, Abrudan, Jenica, Zimmermann, Michael T., Mathison, Angela, Janz, Siegfried, Pufall, Miles A.
Publicado 2023

FOXM1 regulates glycolysis and energy production in multiple myeloma

por Cheng, Yan, Sun, Fumou, Thornton, Krista, Jing, Xuefang, Dong, Jing, Yun, Grant, Pisano, Michael, Zhan, Fenghuang, Kim, Sung Hoon, Katzenellenbogen, John A., Katzenellenbogen, Benita S., Hari, Parameswaran, Janz, Siegfried
Publicado 2022